Dr. Stephanie Venn-Watson

So Jeff did this study and he looked at these kids and he showed that the higher their C15 was correlated with lower liver fat. And this was a linear correlation. So the higher the C15, the lower the fat in the liver. So he's like, okay, well, that's interesting.

So Jeff did this study and he looked at these kids and he showed that the higher their C15 was correlated with lower liver fat. And this was a linear correlation. So the higher the C15, the lower the fat in the liver. So he's like, okay, well, that's interesting.

So Jeff did this study and he looked at these kids and he showed that the higher their C15 was correlated with lower liver fat. And this was a linear correlation. So the higher the C15, the lower the fat in the liver. So he's like, okay, well, that's interesting.

So then that resulted in him doing a randomized placebo controlled clinical trial with fatty 15, with C15 supplementation among young adults who were graduates who had a history of fatty liver disease. And what he found, there were really key important things that happened that he found. The first is he found that two out of three of the people in his study had the definition of a C15 deficiency.

So then that resulted in him doing a randomized placebo controlled clinical trial with fatty 15, with C15 supplementation among young adults who were graduates who had a history of fatty liver disease. And what he found, there were really key important things that happened that he found. The first is he found that two out of three of the people in his study had the definition of a C15 deficiency.

So then that resulted in him doing a randomized placebo controlled clinical trial with fatty 15, with C15 supplementation among young adults who were graduates who had a history of fatty liver disease. And what he found, there were really key important things that happened that he found. The first is he found that two out of three of the people in his study had the definition of a C15 deficiency.

Two thirds. So if you have fatty liver disease, you had an even higher risk of what we were saying the general population has.

Two thirds. So if you have fatty liver disease, you had an even higher risk of what we were saying the general population has.

Two thirds. So if you have fatty liver disease, you had an even higher risk of what we were saying the general population has.

Yeah, exactly. And then for the people who took a C15 supplementation and got their blood levels above that threshold of deficiency, they had lower liver enzymes, lower ALT, lower AST, and improved red blood cell health within 12 weeks. So- Now, the leading hypothesis and what we have found in the dolphins is that nutritional C15 deficiencies may actually

Yeah, exactly. And then for the people who took a C15 supplementation and got their blood levels above that threshold of deficiency, they had lower liver enzymes, lower ALT, lower AST, and improved red blood cell health within 12 weeks. So- Now, the leading hypothesis and what we have found in the dolphins is that nutritional C15 deficiencies may actually

Yeah, exactly. And then for the people who took a C15 supplementation and got their blood levels above that threshold of deficiency, they had lower liver enzymes, lower ALT, lower AST, and improved red blood cell health within 12 weeks. So- Now, the leading hypothesis and what we have found in the dolphins is that nutritional C15 deficiencies may actually

be the cause or at least one cause of a substantial phenotype of fatty liver? Because why did it show up? Why? Like why did this show up all of a sudden? In fact, so many. So that is obviously raising the urgency.

be the cause or at least one cause of a substantial phenotype of fatty liver? Because why did it show up? Why? Like why did this show up all of a sudden? In fact, so many. So that is obviously raising the urgency.

be the cause or at least one cause of a substantial phenotype of fatty liver? Because why did it show up? Why? Like why did this show up all of a sudden? In fact, so many. So that is obviously raising the urgency.

Yeah, and for us, we keep going back to the dolphins. And for the dolphin, we call this the dolphin phenotype of fatty liver disease, the only change they had, they had moved to, they were eating a high fish, high fat fish called the eulachon. which is called a candlefish. It has so much fat in it that you can stick a wick in it. You can dry it, stick a wick in it, and be a candle.

Yeah, and for us, we keep going back to the dolphins. And for the dolphin, we call this the dolphin phenotype of fatty liver disease, the only change they had, they had moved to, they were eating a high fish, high fat fish called the eulachon. which is called a candlefish. It has so much fat in it that you can stick a wick in it. You can dry it, stick a wick in it, and be a candle.

Yeah, and for us, we keep going back to the dolphins. And for the dolphin, we call this the dolphin phenotype of fatty liver disease, the only change they had, they had moved to, they were eating a high fish, high fat fish called the eulachon. which is called a candlefish. It has so much fat in it that you can stick a wick in it. You can dry it, stick a wick in it, and be a candle.

That fishery died out in the 1990s. And so that's when they moved to this lower-fat capelin And so at the same time that humans, we were moving away from whole fat dairy in our C15 sources, the dolphins were moving, going on a low C15 diet, and fatty liver disease pops up.

That fishery died out in the 1990s. And so that's when they moved to this lower-fat capelin And so at the same time that humans, we were moving away from whole fat dairy in our C15 sources, the dolphins were moving, going on a low C15 diet, and fatty liver disease pops up.